Member Info for mulledwine

Manuel Llobet, Chief Executive Officer, commented: "We are pleased that the FDA has decided to lift the clinical hold on our Pollinex Quattro programme. This product has the potential to greatly benefit allergy sufferers in the US in the absence of registered products by being the first subcutaneous immunotherapy vaccine to reach the US market. Additionally, lifting of the hold will allow for discussions with potential partners with whom we will finalise the clinical development and start the commercialisation of Pollinex Quattro in a market estimated to be around US$ 2 billion." Lawrence DuBuske MD, Clinical Professor of Medicine at George Washington University School of Medicine, Washington, DC, principal investigator for the previous phase III study (G301) of the Company's Grass MATA MPL product, the largest ever allergy immunotherapy study to be undertaken, commented: "Grass MATA MPL could revolutionise treatment for grass related allergic rhinitis in the US by providing effective, fast-acting treatment to allergy sufferers. The product involves four pre-seasonal allergy vaccine injections administered over a month, making it an attractive alternative to the prolonged course of weekly to monthly injections over three years that is currently availablewith the allergen extract vaccines used in the United States. There are many patients who decline injections offered by allergists, due to the time commitment and safety concerns when using the typical allergen vaccines now available."

DA Clinical Hold Lifted Phase III Study Agreed Allergy Therapeutics plc, (AIM: Allergy or the "Company"), the specialist pharmaceutical company focused on allergy vaccination, today announces that the FDA has confirmed that the clinical hold in the US dated 2007 has now been lifted on the Company's grass pollen allergy vaccine (Grass MATA MPL/ Pollinex® Quattro Grass 0.5ml) clinical development programme, with immediate effect. Allergy has gained approval to progress with a Phase III efficacy study, to be conducted in an Environmental Exposure Chamber ("EEC"). The Company is now focused on securing a partner to commercialise Pollinex Quattro in the US. Allergy is planning to progress phase III development of their ultra short course allergy vaccines in the US. These 'four shot' products are based on the adjuvant MPL®, the Company's innovative TLR4-agonist which acts to stimulate and re-direct the immune response. The Pollinex Quattro allergy vaccines, which are already commercialised in a number of European countries under a named patient basis, require only four injections per year and have the potential to transform allergy treatment in the US, providing a convenient, safe, and effective vaccination to allergic rhinitis sufferers. The FDA's decision to lift the clinical hold marks an important step in the development of Pollinex Quattro for the treatment of grass allergy in the US.

http://www.investegate.co.uk/Article.aspx?id=201208030700102182J

"The acquisition of Duval provides us with a robust platform for growth in the key Eagle Ford shale region and increases our overall exposure to the US onshore unconventional oil & gas markets," said Derek Blackwood, president-Americas of Wood Group PSN. "Duval's values are similar to Wood Group's, with a strong focus on safety, customers and employees." Rene Casas, president of Wood Group Duval, said "We are pleased to be joining Wood Group. Duval has achieved strong growth over recent years, and we anticipate the strong shale market, momentum in our business and the support of Wood Group will enable continued growth."

ohn Wood Group PLC ("Wood Group") acquisition of Duval Lease Services and Freer Iron Works ("Duval"), increases presence in US Eagle Ford shale region HOUSTON, August 3, 2012-Wood Group has acquired Duval, a provider of maintenance, installation and fabrication services in the Eagle Ford shale region of Texas. Duval, which during the year to December 2011 generated sales of approximately $32m, will operate as Wood Group Duval within Wood Group PSN, and will complement the division's existing onshore US production facilities support services. Duval has approximately 300 personnel and will continue to be led by the existing management team. As at April 2012, Duval held gross assets of $14.0m

http://www.investegate.co.uk/Article.aspx?id=20120803070000P35F9

Outlook During the first half 2012, despite a poor macroeconomic environment and a continuing loss of revenue from government users in Afghanistan, we have made solid progress in returning our Inmarsat Global MSS business to growth. Furthermore, we are seeing sustained take-up and usage growth for our key services, FleetBroadband, IsatPhone Pro, and SwiftBroadband. In the medium term, we remain confident in the prospects for our XpressLink service and in our Global Xpress investment programme. As a result, the outlook statement provided in March 2012 continues to reflect our expectations for the performance of the group and our medium term revenue targets remain unchanged.

Rupert Pearce, Inmarsat's Chief Executive Officer, said, "The results for the first half and second quarter show that we have returned our core MSS business to growth, fuelled by continuing strong subscriber take up and the benefits of pricing initiatives. In light of on-going momentum in subscriber additions, we are making further progress towards meeting our expectations for the full year."

Inmarsat Group Limited - Second Quarter Highlights · Total revenue $329m (2011: $359m) · Inmarsat Global MSS revenue $189m up 4.2% (2011: $181m) · Inmarsat Solutions revenue $205m (2011: $189m) · Total EBITDA $176m (2011: $223m) · MSS active terminals up 13%

London, UK: 3 August 2012. Inmarsat plc (LSE: ISAT.L), the leading provider of global mobile satellite communications services, today provided the following information for the six months ended 30 June 2012. Inmarsat plc - Highlights · Total revenue $684m (2011: $683m) · Inmarsat Global MSS revenue $367m up 1.4% (2011: 362m) · EBITDA $381m (2011: $427m) · EBITDA excluding LightSquared $332m (2011: $336m) · Profit before tax $223m (2011: $255m) · Interim dividend of 16.94 cents (US$), up 10% · Strong growth in Maritime revenue, up 13% · Over 30,000 FleetBroadband terminals installed · Over 65,000 active IsatPhone Pro terminals

http://www.investegate.co.uk/Article.aspx?id=201208030700062036J

Credit Suisse downgrades Atkins (W S) from outperform to neutral, target price cut from 811p to 770p.

N+1 Brewin downgrades RPS Group from buy to add, target price cut from 300p to 275p.

Valuation: Mid-sector range but premium yield The larger stocks in the sector have recovered from their recent lows but are still well below their spring peak as domestic and international economic prospects have faltered. Sector sentiment is unlikely to show substantial recovery short term. Matchtech sits around the middle of the pack on EV/EBITDA, but carries a (covered) 7.4% yield, a premium of over 60%

http://www.edisoninvestmentresearch.co.uk/researchreports/matchtech020812update.pdf

Finncap downgrades Renold from buy to hold, target price cut from 55p to 24p.

BoA Merrill Lynch upgrades National Grid from neutral to buy, target price increased from 660p to 705p.

Future Prospects We have vigorously pursued overseas sales for many years, this now represents 25% of the Company's turnover, and is growing. This is in no small part to the persistence, diligence and organisation of our Sales and Development team, and huge thanks is due to them from me especially. All sales are administered from our Blackpool offices, as are also instructions for production and shipping from the factories in China. With the exception of the UK, we invoice in US Dollars irrespective of the country of destination. This position is a comfort, as the majority of purchases are in Dollars, and the uncertainty of the Sterling/Dollar exchange rate is not so much of an issue. Factors which could be a challenge however are the uncertainties over the future of the Euro, and the possibility of a UK referendum on EU membership. These could adversely affect the Dollar exchange rate and hence our buying and selling prices in the UK. Chinese Labour costs continue to rise, and the decision has been taken to move production of certain items to manufacturing plants in Indonesia, which has lower inflation, stable wages and currency. This is a three year project, and has to be planned carefully. Product tooling, which has to be shipped the 2,500 mile passage, will be out of production for over three months as assembly training will also be required. Further studies are being undertaken to recommence manufacture in the UK. Initially this could concern just two or three products that have minimal assembly costs, and further savings could be made on shipping and import duty. Each would need be designed and retooled to gain maximum cost advantage. In conclusion, I believe the Company has every reason to be optimistic about its future, as long as we remain fully aware of the 'financials' in the current uncertain world. Final Dividend As the Company's future plans will probably require significant investment the Directors recommend a final dividend of 0.75p per share (2011: nil).

Current Trading Having returned from a recent trade fair for the independent toy retailers, I found their demeanour showed a quiet confidence in spite of the gloom from the printed media, and the orders taken were 'par' for the time of year. This was a pleasant surprise as the independent retail sector has had a difficult couple of years, but as many have embraced the additional 'on-line' route they are now reaping the rewards. The high street, grocers and all 'on-line' traders, including the grocers' web sites are showing encouraging sales. This is a good sign for Casdon as our sales are predominantly for the Christmas period, and supports the belief that Brand names are searched for by the 'on-line' buying public.

Chairman's Statement Revenue for the 12 months ended 30th April 2012 of £5,266,073 (2011: £5,360,444) is slightly down on the previous year. We have nevertheless increased our gross profit by ensuring that sales generated are at 'reasonable margins', and benefited from a softening of importation costs from China. These two factors combined to give a gross profit £1,882,726, (2011: £1,704,088). During the year three staff with a combined total of seventy years' service accepted redundancy packages totalling £58,000. These positions have not been replaced with permanent staff. In spite of these costs the Company has generated profit before tax of £215,344 (2011: Loss of £198,744). Our strong balance sheet continues to support the company with fixed assets of £2,336,190 (2011: £2,421,501).